Atossa Therapeutics’ (ATOS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS) in a research report released on Wednesday morning,Benzinga reports. They currently have a $7.00 target price on the stock.

Other equities research analysts have also recently issued research reports about the stock. StockNews.com cut shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 18th. Ascendiant Capital Markets boosted their target price on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a research report on Monday, December 9th.

Atossa Therapeutics Price Performance

ATOS stock opened at $0.72 on Wednesday. The company has a fifty day moving average price of $0.83 and a two-hundred day moving average price of $1.15. Atossa Therapeutics has a one year low of $0.66 and a one year high of $2.31. The stock has a market cap of $90.54 million, a price-to-earnings ratio of -3.27 and a beta of 1.20.

Institutional Investors Weigh In On Atossa Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ATOS. Renaissance Technologies LLC lifted its position in Atossa Therapeutics by 18.9% during the fourth quarter. Renaissance Technologies LLC now owns 1,557,632 shares of the company’s stock worth $1,471,000 after purchasing an additional 247,562 shares during the period. JPMorgan Chase & Co. lifted its position in Atossa Therapeutics by 141.4% during the fourth quarter. JPMorgan Chase & Co. now owns 361,296 shares of the company’s stock worth $341,000 after purchasing an additional 211,654 shares during the period. Virtu Financial LLC lifted its position in Atossa Therapeutics by 311.1% during the fourth quarter. Virtu Financial LLC now owns 208,196 shares of the company’s stock worth $197,000 after purchasing an additional 157,549 shares during the period. Barclays PLC lifted its position in Atossa Therapeutics by 280.9% during the third quarter. Barclays PLC now owns 167,718 shares of the company’s stock worth $255,000 after purchasing an additional 123,683 shares during the period. Finally, Northern Trust Corp lifted its position in Atossa Therapeutics by 7.5% during the fourth quarter. Northern Trust Corp now owns 1,025,724 shares of the company’s stock worth $968,000 after purchasing an additional 71,525 shares during the period. Institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.